Citadel Advisors
BSTG

Citadel Advisors’s Biostage, Inc. Common Stock BSTG Stock Holding History

Citadel Advisors’s Portfolio BSTG Stock Details BSTG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-45,460
Closed -$17K – 8496
2017
Q1 		$17K Buy
+45,460
New +$24.9K ﹤0.01% 7300
2016
Q2 		– Sell
-18,036
Closed -$32K – 7797
2016
Q1 		$32K Buy
+18,036
New +$29.9K ﹤0.01% 6365

Other funds holding BSTG

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAM
Panagora Asset Management Boston, Massachusetts $26.7B AUM 36.4% 1-Year Est. Return
State of New Jersey Common Pension Fund D
State of New Jersey Common Pension Fund D Trenton, New Jersey $25.9B AUM 26.38% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
GWI
Grace & White Inc Ny, New York $632M AUM 34.34% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors's BSTG Position: Q2 2017 in Review

Citadel Advisors sold out of Biostage, Inc. Common Stock (BSTG) in Q2 2017, closing a stake of 45,460 shares — an estimated $17K sold.

Citadel Advisors first reported a position in BSTG in Q1 2016 and held it in 2 quarters. The position peaked at $32K in Q1 2016. 24 funds tracked by Wall St. Rank hold BSTG as of Q2 2017.

  • Citadel Advisors reported no remaining Biostage, Inc. Common Stock position as of Q2 2017 after selling out during the quarter.
  • Citadel Advisors sold 45,460 Biostage, Inc. Common Stock shares in Q2 2017, an estimated $17K.
  • Citadel Advisors first reported a position in Biostage, Inc. Common Stock in Q1 2016 and held it in 2 quarters.
  • Citadel Advisors's Biostage, Inc. Common Stock position peaked at $32K in Q1 2016.
  • 24 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q2 2017.

Based on Citadel Advisors's 13F filing for Q2 2017, filed 11 Aug 2017.